270 related articles for article (PubMed ID: 21208879)
1. Beneficial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results.
van den Berge M; Pauw RG; de Monchy JG; van Minnen CA; Postma DS; Kerstjens HA
Chest; 2011 Jan; 139(1):190-3. PubMed ID: 21208879
[TBL] [Abstract][Full Text] [Related]
2. [Anti IgE antibodies for the treatment of difficult asthma].
Humbert M; Tonnel AB
Rev Mal Respir; 2005 Dec; 22(6 Pt 1):983-90. PubMed ID: 16222222
[TBL] [Abstract][Full Text] [Related]
3. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.
Dal Negro RW; Guerriero M; Micheletto C; Tognella S; Visconti M
J Asthma; 2011 Jun; 48(5):437-41. PubMed ID: 21599560
[TBL] [Abstract][Full Text] [Related]
4. Immunoglobulin E monitoring and reduction of omalizumab therapy in children and adolescents.
Steiss JO; Schmidt A; Nährlich L; Zimmer KP; Rudloff S
Allergy Asthma Proc; 2012; 33(1):77-81. PubMed ID: 22370532
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma.
Somerville L; Bardelas J; Viegas A; D'Andrea P; Blogg M; Peachey G
Curr Med Res Opin; 2014 Jan; 30(1):59-66. PubMed ID: 24028677
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study.
Sheinkopf LE; Rafi AW; Do LT; Katz RM; Klaustermeyer WB
Allergy Asthma Proc; 2008; 29(5):530-7. PubMed ID: 18926061
[TBL] [Abstract][Full Text] [Related]
7. Anti-IgE monoclonal antibody for the treatment of the asthma and other manifestations related to allergic diseases.
Sarinho E; Cruz AA
J Pediatr (Rio J); 2006 Nov; 82(5 Suppl):S127-32. PubMed ID: 17136288
[TBL] [Abstract][Full Text] [Related]
8. Effects of omalizumab in patients with food allergy.
Rafi A; Do LT; Katz R; Sheinkopf LE; Simons CW; Klaustermeyer W
Allergy Asthma Proc; 2010; 31(1):76-83. PubMed ID: 20167148
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab: an effective anti-IgE treatment for allergic asthma and rhinitis.
Casale TB;
Drugs Today (Barc); 2004 Apr; 40(4):367-76. PubMed ID: 15190389
[TBL] [Abstract][Full Text] [Related]
10. [Disease modification and duration of omalizumab treatment in patients with severe allergic asthma].
Schreiber J; Kopp MV; Korn S; Taube C; Buhl R
Pneumologie; 2014 Mar; 68(3):187-92. PubMed ID: 24477463
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of asthma control and quality of life in severe allergic asthmatics under treatment with anti-IgE, omalizumab].
Pacheco-Galván A; Hinojosa-Macías M; Hurtado-Barbudo B; González-Cervera J; Sueiro-Bendito A
Med Clin (Barc); 2009 Oct; 133(12):460-3. PubMed ID: 19775710
[TBL] [Abstract][Full Text] [Related]
12. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma.
Kulus M; Hébert J; Garcia E; Fowler Taylor A; Fernandez Vidaurre C; Blogg M
Curr Med Res Opin; 2010 Jun; 26(6):1285-93. PubMed ID: 20377320
[TBL] [Abstract][Full Text] [Related]
13. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis.
Nayak A; Casale T; Miller SD; Condemi J; McAlary M; Fowler-Taylor A; Della Cioppa G; Gupta N
Allergy Asthma Proc; 2003; 24(5):323-9. PubMed ID: 14619332
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P
J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma.
Berger W; Gupta N; McAlary M; Fowler-Taylor A
Ann Allergy Asthma Immunol; 2003 Aug; 91(2):182-8. PubMed ID: 12952113
[TBL] [Abstract][Full Text] [Related]
16. [Omalizumab, recombinant humanized monoclonal antibody anti-IgE -- new fields of studies on the therapeutic indications].
Kupryś-Lipińska I; Kuna P
Pneumonol Alergol Pol; 2009; 77(1):43-51. PubMed ID: 19308909
[TBL] [Abstract][Full Text] [Related]
17. Basophil histamine release decreases during omalizumab therapy in allergic asthmatics.
Noga O; Hanf G; Kunkel G; Kleine-Tebbe J
Int Arch Allergy Immunol; 2008; 146(1):66-70. PubMed ID: 18087163
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab (Xolair): an anti-IgE antibody for asthma.
Med Lett Drugs Ther; 2003 Aug; 45(1163):67-8. PubMed ID: 12915804
[No Abstract] [Full Text] [Related]
19. Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis.
Incorvaia C; Pravettoni C; Mauro M; Yacoub MR; Tarantini F; Riario-Sforza GG
Monaldi Arch Chest Dis; 2008 Jun; 69(2):78-80. PubMed ID: 18837422
[TBL] [Abstract][Full Text] [Related]
20. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
Holgate ST; Djukanović R; Casale T; Bousquet J
Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
